[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline",
    "summary": "PRINCETON, N.J., May 22, 2025--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline",
    "url": "https://finnhub.io/api/news?id=9fdbd515ff46ea715ce50c9867f40f22ac716500445b416cdfd7cfa9af9b2b4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747947900,
      "headline": "Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline",
      "id": 134658795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., May 22, 2025--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline",
      "url": "https://finnhub.io/api/news?id=9fdbd515ff46ea715ce50c9867f40f22ac716500445b416cdfd7cfa9af9b2b4a"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Yields Vs. Treasury Yields",
    "summary": "While down a bit today, this week has seen a spike in long-term Treasury yields.",
    "url": "https://finnhub.io/api/news?id=e792e6fa8bbe3dc6ed6e95e0ca34feab8eb81f2713b7c25f4a37e996f7f0ca86",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747926900,
      "headline": "Dividend Yields Vs. Treasury Yields",
      "id": 134652844,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407983911/image_1407983911.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "While down a bit today, this week has seen a spike in long-term Treasury yields.",
      "url": "https://finnhub.io/api/news?id=e792e6fa8bbe3dc6ed6e95e0ca34feab8eb81f2713b7c25f4a37e996f7f0ca86"
    }
  },
  {
    "ts": null,
    "headline": "1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About",
    "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
    "url": "https://finnhub.io/api/news?id=7ed79cab9144d716799c45eae560bd484658ae1013819c18a100392e5499fcb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747888494,
      "headline": "1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About",
      "id": 134648107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
      "url": "https://finnhub.io/api/news?id=7ed79cab9144d716799c45eae560bd484658ae1013819c18a100392e5499fcb0"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)",
    "summary": "Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.",
    "url": "https://finnhub.io/api/news?id=280b9ff331a98cc0484ab060858e98a391f48da5585fe3ae814cbcd058b6b35a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747884660,
      "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)",
      "id": 134658712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.",
      "url": "https://finnhub.io/api/news?id=280b9ff331a98cc0484ab060858e98a391f48da5585fe3ae814cbcd058b6b35a"
    }
  }
]